T1	p 72 123	zoster vaccine in healthy adults ?60 years of age .
T2	p 161 176	herpes zoster (
T3	p 186 198	postherpetic
T4	p 507 547	with 210 subjects ?60 years old compared
T5	p 1674 1696	adults ?60 years old .
T6	i 343 345	ZV
T7	i 448 450	ZV
T8	i 604 606	ZV
T9	i 622 660	6 weeks , vs. placebo . Immunogenicity
T10	i 675 832	using VZV interferon-gamma ( IFN-? ) enzyme-linked immunospot ( ELISPOT ) assay and VZV glycoprotein enzyme-linked immunosorbent antibody ( gpELISA ) assay .
T11	i 841 860	experiences ( AEs )
T12	i 893 904	Vaccination
T13	i 912 916	Card
T14	i 1304 1311	placebo
T15	i 1500 1507	placebo
T16	i 1623 1625	ZV
T17	i 1714 1716	ZV
T18	o 6 48	Safety , tolerability , and immunogenicity
T19	o 161 174	herpes zoster
T20	o 561 567	safety
T21	o 646 660	Immunogenicity
T22	o 681 860	VZV interferon-gamma ( IFN-? ) enzyme-linked immunospot ( ELISPOT ) assay and VZV glycoprotein enzyme-linked immunosorbent antibody ( gpELISA ) assay . Adverse experiences ( AEs )
T23	o 880 918	standardized Vaccination Report Card .
T24	o 927 1095	No serious vaccine-related AEs occurred . VZV IFN-? ELISPOT geometric mean count ( GMC ) of spot-forming cells per 10 ( 6 ) peripheral blood mononuclear cells increased
T25	o 1232 1240	postdose
T26	o 1245 1248	GMC
T27	o 1352 1377	The peak ELISPOT response
T28	o 1421 1459	gpELISA geometric mean titers ( GMTs )
T29	o 1563 1599	the IFN-? ELISPOT and gpELISA assays
T30	o 1640 1670	well-tolerated and immunogenic
T31	o 1731 1735	safe
T32	o 1756 1777	VZV-specific immunity
T33	o 1801 1809	postdose